A cd47 mutant and applications thereof
By removing the transmembrane and intracellular regions of CD47, retaining the IgV domain and linking it to GPI, a CD47 mutant was generated. This solved the problem of separating the beneficial and negative effects of CD47 in transplantation, and achieved efficient graft survival and functional enhancement.
CN122161860APending Publication Date: 2026-06-05XUSHIYUAN BIOTECHNOLOGY (SHANGHAI) CO LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- XUSHIYUAN BIOTECHNOLOGY (SHANGHAI) CO LTD
- Filing Date
- 2024-11-01
- Publication Date
- 2026-06-05
Smart Images
Figure CN122161860A_ABST
Abstract
The present application provides a kind of CD47 mutant and its application, wherein CD47 mutant includes the amino acid sequence of partial amino acid sequence of CD47 and glycosyl phosphatidyl inositol (GPI) connection signal.The CD47 mutant is obtained by removing potential cell survival inhibition, blood flow and angiogenesis inhibition and other negative effect signal transduction sequences (transmembrane region and intracellular region) in CD47, while the beneficial functional segment (extracellular IgV domain) involved in inhibiting the phagocytosis of myeloid cells and its cytotoxic activity in CD47 sequence is fused with GPI membrane anchor connection signal sequence from human decay accelerating factor (DAF) protein.The obtained CD47 mutant can protect cells and organ transplants from being mediated by myeloid cells and other SIRP alpha positive immune cells with equal efficacy to wild type CD47, and at the same time eliminates the negative effects of wild type CD47.
Need to check novelty before this filing date? Find Prior Art